Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-Mesothelin CAR-NK Cells in Epithelial Ovarian Cancer
NCT03692637Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR-NK cells in epithelial ovarian cancer (EOC), sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events. Status: unknown.
02
Drugs
anti-mesothelin CAR-NK cells
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT03692637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692637.